[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f4JetHCCbzg76LwXsOdASTASSYYPlZJ3TpBU6HmF0li4":8,"$feTou-2gIAYnQkT-Ryo9WYrp6C88tKw15JxOItEN_zmE":57,"$fp85e11MAifxOs_nphiT2pBT5kw0MUr6417BlIscC_gQ":58,"$focNSErQJmvYD1RNrNIrg1vkMXmBoYQQjZxe6cdNH9JQ":62},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":56},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"roleType":6,"adept":17,"hospital":18,"department":19,"postsTitle":20,"materialTotal":21,"videoTotal":22,"isConcern":7,"title":23,"coverVertical":17,"coverAcross":24,"directionMarker":25,"description":26,"vid":27,"time":28,"mediaType":25,"views":29,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":30,"seoTitle":31,"seoKeywords":32,"seoDescription":33,"shelvesTime":34,"menus":35,"menuId":37,"type":54,"quality":6,"commentCount":21,"isComment":25,"deviceType":22,"url":55},14137,871759,[],"https://ystcdn.venuertc.com/venue/app/24723/2026-06-16/4b86fb7a-2f8e-4922-9239-0e340dc22e9e.png","吕诗凡","","上海交通大学医学院附属仁济医院","急诊科","住院医师",0,4,"恶性胸腔积液诊疗及其后续康复","https://cdn.yishi-tong.com/console/3/0FFBgh_AIfs2QRTjimh_l8jcnOoXSFgw.png",1,"WEBVTT\n\n00:00.937 --> 00:04.186\n恶性胸腔积液诊疗及其后续康复。\n\n00:05.881 --> 00:10.331\n恶性胸腔积液是指原发于胸膜的恶性肿瘤或其他部位的恶性肿瘤，\n\n00:10.331 --> 00:12.331\n转移至胸膜引起的胸腔积液。\n\n00:12.581 --> 00:15.930\n目前国内外尚缺乏流行病学的调查研究资料。\n\n00:16.031 --> 00:16.781\n据统计，\n\n00:16.830 --> 00:19.830\n美国每年的MB患者超过15万人，\n\n00:20.031 --> 00:22.180\n几乎所有肿瘤均可出现MPE。\n\n00:22.180 --> 00:23.781\n肺癌是最常见的病因，\n\n00:23.781 --> 00:25.481\n约占MPE的1/3，\n\n00:25.531 --> 00:26.981\n乳腺癌位居第二，\n\n00:27.031 --> 00:29.381\n淋巴瘤也是导致MPE的重要原因，\n\n00:29.381 --> 00:31.781\n卵巢和胃肠道的肿瘤也可以引起，\n\n00:31.930 --> 00:32.930\n但较少见。\n\n00:32.980 --> 00:36.081\n约5%.10%的MPE找不到原发肿瘤。\n\n00:36.108 --> 00:36.257\n六。\n\n00:37.433 --> 00:40.034\nMPE提示肿瘤播散或进展至晚期，\n\n00:40.183 --> 00:42.183\n患者预期寿命显著缩短。\n\n00:42.234 --> 00:43.933\n从确立诊断开始计算，\n\n00:43.933 --> 00:46.133\n中位生存期为3.12个月，\n\n00:46.383 --> 00:49.734\n具体原发肿瘤类型和免疫分期密切相关。\n\n00:49.984 --> 00:51.234\n已有证据显示，\n\n00:51.234 --> 00:53.784\n肺癌所致MPE患者生存期最短，\n\n00:53.883 --> 00:56.333\n卵巢癌所致MPE生存期最长。\n\n00:57.129 --> 01:02.979\n而无法找到原发灶的MPE患者生存期介于上述两者之间。\n\n01:02.979 --> 01:08.028\nMPE患者生存质量主要受呼吸困难、胸痛、咳嗽等症状严重程度影响，\n\n01:08.128 --> 01:13.329\n同时与营养状况、心理状态及治疗相关并发症密切相关。\n\n01:14.646 --> 01:14.746\n嗯，\n\n01:14.746 --> 01:15.445\n早期诊断，\n\n01:15.445 --> 01:16.945\n及时有效的姑息治疗，\n\n01:16.996 --> 01:20.896\n如胸膜固定术及以及积极控制原发肿瘤，\n\n01:20.896 --> 01:21.820\n是缓解症状，\n\n01:21.820 --> 01:22.871\n延长生存期，\n\n01:22.871 --> 01:25.695\n提高MP患者生存质量的重要措施。\n\n01:28.138 --> 01:28.737\n发病机制。\n\n01:29.974 --> 01:30.900\n正常情况下，\n\n01:30.900 --> 01:34.150\n胸膜腔内液体由壁层胸膜毛细血管滤出，\n\n01:34.150 --> 01:37.824\n经脏层胸膜毛细血管和淋巴管重吸收。\n\n01:37.824 --> 01:38.699\n正常情况下，\n\n01:38.699 --> 01:40.949\n滤出与重吸收处于动态平衡，\n\n01:41.300 --> 01:44.449\n胸腔内液体量保持稳定，\n\n01:44.449 --> 01:50.550\n包括胸膜毛细血管内压、胶体渗透压、毛细血管通透性及胸腔内压力。\n\n01:50.550 --> 01:52.125\n当这些因素发生改变，\n\n01:52.125 --> 01:55.800\n如毛细血管内压升高或胶体渗透压降低，\n\n01:55.800 --> 01:58.400\n均可打破平衡导致胸腔积液形成。\n\n01:58.800 --> 02:00.000\n恶性肿瘤可。\n\n02:00.096 --> 02:01.896\n通过影响淋巴管回流，\n\n02:01.996 --> 02:05.695\n侵犯胸膜或阻塞支气管致肺不张，\n\n02:05.945 --> 02:07.670\n刺激胸膜产生炎症反应，\n\n02:07.670 --> 02:09.345\n增加毛细血管通透性，\n\n02:09.395 --> 02:10.895\n引发低蛋白血症，\n\n02:10.945 --> 02:15.595\n降低胶体渗透压等多种途径导致胸膜腔内液体异常积聚。\n\n02:19.005 --> 02:23.305\n肿瘤相关胸腔积液形成主要由淋巴回流障碍，\n\n02:23.305 --> 02:25.055\n胸膜直接侵犯与种植，\n\n02:25.106 --> 02:26.830\n毛细血管通透性增加，\n\n02:26.830 --> 02:29.205\n胸腔内压降低与肺不张，\n\n02:29.205 --> 02:33.406\n全身性因素影响常见肿瘤类型分布，\n\n02:33.455 --> 02:34.656\n肺癌最常见，\n\n02:34.656 --> 02:36.156\n其次是乳腺癌，\n\n02:36.255 --> 02:38.505\n淋巴瘤也是重要的致病因素。\n\n02:38.656 --> 02:39.130\n另外，\n\n02:39.130 --> 02:39.906\n卵巢癌，\n\n02:40.005 --> 02:42.255\n胃肠道癌也可引起胸腔积液。\n\n02:42.305 --> 02:42.731\n另外，\n\n02:42.731 --> 02:47.455\n有约5%.10%的恶性胸腔积液病例是找不到原发肿瘤病灶的。\n\n02:47.970 --> 02:49.621\n三临床表现与诊断。\n\n02:50.574 --> 02:52.324\n主要临床表现是呼吸困难，\n\n02:52.475 --> 02:54.625\n与积液量及增长速度相关，\n\n02:54.625 --> 02:56.425\n严重时可出现端坐呼吸，\n\n02:56.625 --> 02:59.024\n约25%的患者可无症状。\n\n02:59.024 --> 03:02.574\n通过体检或影像学检查偶然发现胸痛，\n\n03:02.574 --> 03:04.425\n多为钝痛或隐痛，\n\n03:04.625 --> 03:08.625\n与胸与肿瘤侵犯胸膜或肋间神经有关，\n\n03:08.675 --> 03:12.824\n或伴有干咳、体重减轻、乏力、食欲减退等全身症状。\n\n03:13.125 --> 03:15.875\n查血提示可能存在肺内原发肿瘤。\n\n03:16.587 --> 03:18.061\n患侧胸廓饱满，\n\n03:18.061 --> 03:19.337\n呼吸运动减弱，\n\n03:19.486 --> 03:22.111\n触觉语颤减弱或消失，\n\n03:22.111 --> 03:23.936\n叩诊呈实音或浊音，\n\n03:24.287 --> 03:26.386\n听诊呼吸音减弱或消失。\n\n03:27.166 --> 03:27.365\n嗯，\n\n03:27.865 --> 03:31.115\n大量积液可伴有气管纵隔向健侧移位。\n\n03:31.416 --> 03:33.166\n影像学检查技术对比，\n\n03:33.365 --> 03:36.740\n胸部X线可显示中至大量胸腔积液，\n\n03:36.740 --> 03:38.315\n表现为肋膈角变钝，\n\n03:38.365 --> 03:40.466\n中下肺野均匀致密影。\n\n03:40.466 --> 03:42.291\n约10%为大量积液，\n\n03:42.291 --> 03:44.115\n15%为少量积液。\n\n03:44.365 --> 03:48.266\n卧位射偏有助于鉴别游离性与包裹性积液，\n\n03:48.315 --> 03:50.416\n但对少量积液敏感性较低。\n\n03:51.393 --> 03:54.768\n超声能精准识别积液量及分隔情况，\n\n03:54.768 --> 03:56.593\n实时引导穿刺抽液，\n\n03:56.694 --> 03:59.544\n减少气胸、出血等并发症风险，\n\n03:59.593 --> 04:01.593\n有助于了解胸膜受累情况，\n\n04:01.593 --> 04:04.994\n评估积液粘粘稠度和内容物，\n\n04:04.994 --> 04:08.194\n是少量胸腔穿刺术定位的首选方法。\n\n04:08.917 --> 04:09.692\nCT,\n\n04:09.692 --> 04:12.292\n高分辨率CT可区分积液性质，\n\n04:12.492 --> 04:15.266\n检出潜在病因，\n\n04:15.266 --> 04:17.242\n如肿瘤、肺炎或胸膜增厚，\n\n04:17.342 --> 04:19.242\n有助于发现恶性肿瘤患者。\n\n04:19.242 --> 04:22.842\n少量MPE判断是否伴有纵隔淋巴结转移，\n\n04:23.092 --> 04:25.941\n评估肿瘤侵犯纵隔或胸壁范围，\n\n04:25.992 --> 04:26.992\n发现胸膜斑，\n\n04:26.992 --> 04:28.391\n提示石棉暴露史。\n\n04:29.141 --> 04:29.516\nMi,\n\n04:29.566 --> 04:29.967\n对。\n\n04:30.954 --> 04:32.204\nMPE诊断价值有限，\n\n04:32.204 --> 04:36.529\n但可能有助于评估肿瘤侵犯纵膈或胸壁的范围。\n\n04:36.529 --> 04:39.079\nPet CT对MPE具有良好的预测价值，\n\n04:39.230 --> 04:41.529\n可观察肿瘤细胞转移及活性，\n\n04:41.579 --> 04:43.079\n明确病情分期，\n\n04:43.329 --> 04:46.380\n但有待更多循证医学证据支持。\n\n04:46.829 --> 04:50.730\n实验室诊断与与标准与流程首先，\n\n04:50.779 --> 04:55.179\n渗出液与漏出液的鉴别采用的是let标准进行鉴别。\n\n04:55.380 --> 04:55.829\n另外，\n\n04:55.829 --> 05:00.480\n胸腔积液常规实验室检查包括有核细胞计数、分分类。\n\n05:01.274 --> 05:05.225\n总蛋白、葡萄糖、LDH、淀粉酶及肿瘤细胞学检查。\n\n05:06.049 --> 05:06.250\n嗯。\n\n05:07.446 --> 05:10.996\n生水细胞学检查是确诊MPE最简单的方法，\n\n05:11.145 --> 05:14.395\n诊断率在62%.90%之间，\n\n05:14.496 --> 05:16.645\n多次检测可提高阳性率。\n\n05:19.484 --> 05:23.734\n肿瘤标志物如癌胚抗原细胞角蛋白片21-1，\n\n05:23.734 --> 05:26.533\nC 125153199,\n\n05:26.584 --> 05:29.084\n敏感度为40%.60%，\n\n05:29.084 --> 05:31.283\n特异度可达80%.90%。\n\n05:31.634 --> 05:34.884\n联合检测多种指标可提高诊断效率。\n\n05:35.884 --> 05:39.183\n粘液组化染色和染色体分析可辅助诊断。\n\n05:39.283 --> 05:42.783\n染色体分析在白血病和淋巴瘤诊断中有帮助。\n\n05:42.933 --> 05:46.984\n确诊的金标准是在胸水细胞沉淀中找到恶性细胞，\n\n05:47.084 --> 05:50.984\n或在胸膜活检组织中观察到恶性肿瘤的病理变化。\n\n05:51.759 --> 05:52.959\n有创性检查技术。\n\n05:54.201 --> 06:02.451\n可以包括诊断性胸腔穿刺、闭式胸膜活检、内科胸腔镜检查、外科活检术以及支气管镜检查等。\n\n06:04.071 --> 06:05.272\n多学科治疗策略。\n\n06:06.759 --> 06:12.808\n治疗性胸腔穿刺的规范适用于预期寿命短、体能状况差的终末期患者，\n\n06:12.908 --> 06:14.908\n可暂时缓解呼吸困难症状。\n\n06:14.959 --> 06:18.308\n胸腔穿刺排液后一个月内MPE复发率较高。\n\n06:18.359 --> 06:22.259\n不推荐用于预售预期寿命超过一个月的患者，\n\n06:22.509 --> 06:25.509\n相对禁忌症包括少量胸水出血倾向。\n\n06:27.217 --> 06:29.967\n正在接受抗凝治疗和机械通气等情况。\n\n06:30.902 --> 06:35.052\n一般首次胸腔穿刺排液量在800ml以内，\n\n06:35.101 --> 06:37.002\n最多不超过1500ml。\n\n06:37.252 --> 06:40.851\n对纵隔移位的MPE患者可酌情增加抽液量。\n\n06:40.951 --> 06:42.951\n排液过程中应缓慢抽液。\n\n06:42.951 --> 06:46.402\n警惕复张性肺水肿、胸膜反应等并发症。\n\n06:46.652 --> 06:52.851\n术后需密切观察患者呼吸频率、节律、血氧饱和度及有无头晕、心悸等症状。\n\n06:52.951 --> 06:56.201\n主要并发症包括胸膜反应、气胸、出血等，\n\n06:56.252 --> 06:57.076\n一旦发生，\n\n06:57.076 --> 06:58.502\n需立即停止操作，\n\n06:58.502 --> 06:59.802\n并给予对症处理。\n\n07:00.984 --> 07:05.334\n胸膜固定术临床医院适用于预期生存期大于1个月，\n\n07:05.334 --> 07:08.535\n肺可复张的复发性恶性胸腔积液患者，\n\n07:08.635 --> 07:10.285\n尤其推荐用于肺癌，\n\n07:10.285 --> 07:12.285\n乳腺癌等所致的MPE。\n\n07:12.434 --> 07:16.285\n对肺萎陷或严重恶病质患者需谨慎评估，\n\n07:16.484 --> 07:19.984\n需在超声或CT引导下置入小孔径引流管，\n\n07:19.984 --> 07:25.184\n充分引流胸水注射硬化剂前需经引流管给予利多卡因，\n\n07:25.184 --> 07:25.734\n局麻。\n\n07:25.834 --> 07:28.209\n术后夹管一小时，\n\n07:28.209 --> 07:29.434\n24.48小时内拔管。\n\n07:30.289 --> 07:32.389\n滑石粉为首选的硬化剂，\n\n07:32.639 --> 07:34.789\n菌粒滑石粉安全性更高，\n\n07:34.789 --> 07:36.938\n剂量2.5.10毫10g，\n\n07:37.188 --> 07:40.088\n胸膜固定成功率可达70%.90%。\n\n07:40.289 --> 07:41.963\n博来霉素为替代选择，\n\n07:41.963 --> 07:42.739\n疗效中等，\n\n07:42.739 --> 07:44.489\n适用于滑石粉禁忌者，\n\n07:44.739 --> 07:49.039\n主要并发症包括胸痛、发热、罕见低氧血症及感染。\n\n07:49.139 --> 07:50.088\n术前镇痛，\n\n07:50.088 --> 07:51.313\n术中规范操作，\n\n07:51.313 --> 07:52.789\n术后监测生命体征，\n\n07:52.889 --> 07:54.438\n可有效降低风险。\n\n07:54.588 --> 07:56.639\n肺萎线是失败的主要原因。\n\n07:57.855 --> 08:07.404\n胸腔内药物治疗方案包括化疗药物、胸腔灌注、抗血管生成药药物应用、生物反应调节剂治疗以及胸膜硬化剂的选择。\n\n08:08.781 --> 08:09.730\n外科干预进展。\n\n08:10.609 --> 08:16.709\n外科胸腔镜需全身麻醉及双腔气管插管单侧肺通气实现更广视野，\n\n08:16.709 --> 08:19.510\n可同时完成诊断与治疗操作。\n\n08:19.559 --> 08:24.609\n对内科胸腔镜无法耐受单肺通气患者为重要替代方案。\n\n08:24.660 --> 08:27.510\n滑石粉作为最有效的硬化剂菌粒，\n\n08:27.510 --> 08:31.410\n滑石粉较非菌粒可降低低氧血症风险，\n\n08:31.709 --> 08:35.309\n喷洒粉末与注射匀浆疗效相当。\n\n08:35.409 --> 08:37.984\n国内医医用滑石粉生产限制，\n\n08:37.984 --> 08:40.809\n暂未常规开展门诊长期流。\n\n08:40.880 --> 08:45.780\n置胸腔引流管适用于肺萎线或需短缩短住院时间的患者，\n\n08:45.830 --> 08:50.780\n通过间歇性连接真空引流瓶促进肺复张与胸腔闭锁。\n\n08:51.030 --> 08:53.580\n多数患者短期流感后可拔除。\n\n08:54.267 --> 08:56.067\n对恶性胸膜间皮瘤患者，\n\n08:56.067 --> 09:01.966\n大口径引流管置入处、胸腔镜操作部位及手术切口需预防性放射治疗，\n\n09:02.216 --> 09:04.466\n降低肿瘤细胞种植转移风险，\n\n09:04.567 --> 09:08.617\n穿刺处及胸膜活检处无需常规预防放疗。\n\n09:10.986 --> 09:12.786\n五急性期护理要点。\n\n09:14.564 --> 09:16.463\n一呼吸功能动态监测，\n\n09:16.614 --> 09:19.888\n持续监测血氧饱和度、呼吸频率、节律及深度，\n\n09:19.888 --> 09:21.664\n结合动脉血气分析，\n\n09:21.763 --> 09:23.664\n评估氧合及通气功能，\n\n09:23.713 --> 09:26.463\n及时发现低氧血症或呼吸衰竭倾向。\n\n09:26.564 --> 09:28.289\n每日听诊双肺呼吸音，\n\n09:28.289 --> 09:29.138\n关注积液，\n\n09:29.138 --> 09:32.763\n侧呼吸音减弱或消失、湿啰音等异常体征。\n\n09:33.866 --> 09:35.765\n呼吸困难程度量化评估。\n\n09:35.916 --> 09:37.265\n采用VAS或。\n\n09:38.122 --> 09:40.973\n量表患者主观呼吸困难感受，\n\n09:41.072 --> 09:43.797\n结合活动耐力测试综合判断。\n\n09:43.797 --> 09:44.922\n病情进展中，\n\n09:44.922 --> 09:47.598\n大量积液患者多出现明显呼吸困难，\n\n09:47.598 --> 09:49.672\n需优先干预氧疗。\n\n09:49.922 --> 09:53.523\n根据血氧饱和度及呼吸困难程度调整氧流方案，\n\n09:53.523 --> 09:55.348\n一般给予低流量吸氧，\n\n09:55.348 --> 09:58.322\n以维持SPO2≥90%。\n\n09:58.572 --> 10:01.572\n对于严重低氧血症或高碳酸血症患者，\n\n10:01.672 --> 10:03.523\n需遵医嘱调整氧流量，\n\n10:03.523 --> 10:06.773\n或改用无创或有创呼吸机辅助通气。\n\n10:07.500 --> 10:10.200\n指导患者采用半卧位或患侧卧位，\n\n10:10.601 --> 10:12.726\n减轻胸水对肺组织的压迫，\n\n10:12.726 --> 10:13.601\n改善通气。\n\n10:13.700 --> 10:17.901\n鼓励患者进行深呼吸、有效咳嗽及腹式呼吸训练，\n\n10:17.901 --> 10:19.301\n每日3.4次，\n\n10:19.301 --> 10:20.851\n每次10.15分钟，\n\n10:21.051 --> 10:23.151\n促进肺复张及痰液排出。\n\n10:24.677 --> 10:26.328\n胸腔引流管护理规范，\n\n10:26.328 --> 10:28.203\n要注意无菌操作与感染，\n\n10:28.203 --> 10:29.502\n预防引流管通畅，\n\n10:29.502 --> 10:30.828\n维护引流液，\n\n10:30.828 --> 10:32.627\n观察与记录拔管指征。\n\n10:32.978 --> 10:36.028\n一般当24小时引流量少于100ml，\n\n10:36.078 --> 10:38.528\n胸部X线证实肺完全复张，\n\n10:38.578 --> 10:40.752\n且患者呼吸困难症状缓解时，\n\n10:40.752 --> 10:41.728\n可考虑拔管。\n\n10:41.927 --> 10:44.302\n拔管前夹闭引流管24小时，\n\n10:44.302 --> 10:45.728\n观察患者无不适，\n\n10:45.877 --> 10:46.903\n消毒穿刺点，\n\n10:46.903 --> 10:48.177\n迅速拔出引流管，\n\n10:48.278 --> 10:50.328\n覆盖无菌敷料并加压包扎，\n\n10:50.478 --> 10:54.877\n拔管后24小时内观察有无胸闷、气促、皮下气肿等并发症。\n\n10:56.333 --> 10:58.182\n疼痛多模式管理策略。\n\n11:00.934 --> 11:03.283\n采用各种量表评分，\n\n11:03.283 --> 11:04.783\n量化疼痛程度，\n\n11:04.783 --> 11:08.633\n重点评估疼痛性质、部位、持续时间及诱发因素，\n\n11:08.633 --> 11:10.283\n为治疗方案提供依据。\n\n11:10.434 --> 11:12.333\n遵循三阶梯止痛原则，\n\n11:12.434 --> 11:15.083\n轻度疼痛选用非甾体类抗炎药，\n\n11:15.083 --> 11:17.583\n中重度疼痛联合阿片类药物。\n\n11:17.984 --> 11:22.133\n非药物镇痛技术指导患者采取舒适舒适体位。\n\n11:22.184 --> 11:26.883\n通过深呼吸训练、渐进性肌肉松弛、音乐疗法等分散注意力，\n\n11:26.883 --> 11:30.033\n配合冷敷或胸壁物理治疗缓解疼痛。\n\n11:30.562 --> 11:32.413\n每4小时评估疼痛变化，\n\n11:32.513 --> 11:34.963\n记录药物疗效及不良反应。\n\n11:35.013 --> 11:37.713\n根据评估结果及时调整镇痛方案，\n\n11:37.713 --> 11:40.312\n确保疼痛评分维持在3分以下。\n\n11:43.031 --> 11:44.731\n并发症预防与应急处理，\n\n11:45.231 --> 11:46.581\n严格无菌操作，\n\n11:46.581 --> 11:48.132\n定期更换引流装置，\n\n11:48.132 --> 11:49.956\n保持穿刺点清洁干燥，\n\n11:49.956 --> 11:50.831\n定期消毒，\n\n11:50.932 --> 11:52.956\n监测体温及引流液性状，\n\n11:52.956 --> 11:55.731\n出现发热、引流液浑浊或异味时，\n\n11:55.731 --> 11:56.932\n及时报告医生，\n\n11:56.981 --> 12:03.182\n并遵循医嘱使用抗生素控制引流液引流速度和首次引流量。\n\n12:03.281 --> 12:08.481\n密切观察有无咳嗽、气促加重、咳大量白色泡沫痰等症状。\n\n12:08.481 --> 12:09.156\n一旦发生，\n\n12:09.156 --> 12:10.382\n立即停止引流，\n\n12:10.481 --> 12:11.331\n取半卧位，\n\n12:11.331 --> 12:12.382\n高流量吸氧，\n\n12:12.432 --> 12:13.231\n遵医嘱。\n\n12:13.268 --> 12:15.317\n应用利尿剂及糖皮质激素。\n\n12:16.065 --> 12:17.916\n出血预防及应急处理，\n\n12:17.966 --> 12:19.866\n穿刺前评估凝血功能。\n\n12:19.866 --> 12:23.015\n对于出血、出血倾向患者谨慎操作，\n\n12:23.166 --> 12:29.616\n操作中及时术前及术后密切观察引流液颜色、量及生命体征。\n\n12:29.716 --> 12:31.265\n若引流液为鲜红色，\n\n12:31.265 --> 12:32.390\n且量持续增加，\n\n12:32.390 --> 12:33.666\n或出现血压下降，\n\n12:33.716 --> 12:34.541\n心率加快，\n\n12:34.541 --> 12:35.591\n立即通知医生，\n\n12:35.591 --> 12:37.716\n做好输血止血等急救准备。\n\n12:38.562 --> 12:41.562\n胸膜反应操作前向患者做好解释，\n\n12:41.612 --> 12:42.963\n消除紧张情绪。\n\n12:43.163 --> 12:49.038\n操作中密切观察患者面色、心率、血压及有无头晕、出汗、心悸等症状，\n\n12:49.038 --> 12:49.713\n一旦发生，\n\n12:49.713 --> 12:50.913\n立即停止操作。\n\n12:51.062 --> 12:52.138\n让患者平卧，\n\n12:52.138 --> 12:55.163\n必要时皮下注射肾上腺素吸氧，\n\n12:55.163 --> 12:56.763\n并遵医嘱对症处理。\n\n12:58.835 --> 13:00.335\n六康复期综合管理。\n\n13:02.184 --> 13:10.508\n呼吸功能康复训练包括腹式呼吸训练、缩唇呼吸训练、呼吸机力量训练、有效咳痰、咳嗽排痰训练，\n\n13:10.508 --> 13:12.434\n营养支持方案制定，\n\n13:12.734 --> 13:14.484\n营养状况全面评估。\n\n13:14.633 --> 13:17.734\n通过体重变化、血红蛋白等指标，\n\n13:18.033 --> 13:21.083\n结合患者食欲、进食量及消化吸收功能，\n\n13:21.083 --> 13:24.633\n全面评估恶性肿瘤、胸腔积液患者的营养状态，\n\n13:24.684 --> 13:27.234\n为个性化方案治疗提供依据。\n\n13:27.721 --> 13:29.671\n个性化饮食计划及构建，\n\n13:29.721 --> 13:32.770\n基于患者口味偏好与营养需求设计，\n\n13:32.770 --> 13:34.120\n高蛋白、高热量。\n\n13:35.021 --> 13:37.271\n富含维生素及矿物质的饮食方案，\n\n13:37.271 --> 13:38.396\n鼓励少食多餐，\n\n13:38.396 --> 13:40.721\n避免一次进食过多引起腹胀。\n\n13:41.221 --> 13:43.471\n优先选择肠内营养支持治疗，\n\n13:43.471 --> 13:45.747\n如经口进食无法满足需求，\n\n13:45.747 --> 13:48.072\n可给予鼻饲营养液，\n\n13:48.171 --> 13:49.997\n逐步增加输液量与浓度，\n\n13:49.997 --> 13:51.322\n监测耐受情况。\n\n13:51.421 --> 13:54.296\n对于严重营养不良或肠内营养不耐受者，\n\n13:54.296 --> 13:56.171\n遵医嘱实施肠外营养支持，\n\n13:56.521 --> 14:00.947\n通过静脉补充葡萄糖、氨基酸、脂肪、乳剂等营养素，\n\n14:00.947 --> 14:02.471\n维持水、电解质平衡。\n\n14:03.702 --> 14:06.052\n四营养效果动态监测与调整。\n\n14:06.836 --> 14:10.986\n定期监测患者体重、血清白蛋白、前白蛋白等营养指标，\n\n14:11.137 --> 14:13.336\n评估营养支持效果。\n\n14:13.437 --> 14:18.836\n根据监测结果及时调整饮食结构、营养剂种类或输液速度，\n\n14:18.887 --> 14:21.387\n确保营养支持的有效性与安全性，\n\n14:21.387 --> 14:22.736\n避免并发症的发生。\n\n14:24.125 --> 14:25.926\n心理社会体系的支持，\n\n14:26.176 --> 14:29.375\n患者心理状态评估与干预恶性肿瘤，\n\n14:29.375 --> 14:31.426\n胸腔积液患者常因呼吸困难，\n\n14:31.426 --> 14:33.776\n疼痛及对疾病预后的担忧，\n\n14:33.776 --> 14:34.750\n易出现焦虑，\n\n14:34.750 --> 14:35.250\n抑郁，\n\n14:35.250 --> 14:36.575\n恐惧等负面情绪。\n\n14:36.676 --> 14:38.950\n护理人员应采用标准化量表，\n\n14:38.950 --> 14:40.926\n定期评估患者的生理状态，\n\n14:41.026 --> 14:42.375\n识别高危人群，\n\n14:42.526 --> 14:44.575\n及时进行针对性心理疏导，\n\n14:44.625 --> 14:46.450\n帮助患者缓解心理压力，\n\n14:46.450 --> 14:47.575\n树立治疗信心。\n\n14:47.926 --> 14:51.426\n家属是患者重要的社会资源支持来源，\n\n14:51.575 --> 14:54.325\n护理人员需向家属提供疾病相关。\n\n14:54.364 --> 14:55.713\n知识护理技能培训，\n\n14:55.763 --> 15:00.064\n指导家属给予患者情绪、情感支持和生活照顾，\n\n15:00.164 --> 15:02.189\n同时关注家属的心理需求，\n\n15:02.189 --> 15:03.664\n提供必要的心理疏导，\n\n15:03.864 --> 15:06.713\n社会资源链条链接与利用。\n\n15:07.469 --> 15:08.919\n积极链接社会资源，\n\n15:08.969 --> 15:10.895\n为患者提供多方面支持，\n\n15:10.895 --> 15:14.520\n包括介绍肿瘤患者互助团体、康复机构，\n\n15:14.520 --> 15:17.070\n协助申请医疗救助或慈善帮扶，\n\n15:17.219 --> 15:19.320\n提供心理咨询热线等信息。\n\n15:19.419 --> 15:20.820\n通过整合社会力量，\n\n15:20.820 --> 15:25.744\n帮助患者及家属获得更多的情感支持、经济援助和康复指导，\n\n15:25.744 --> 15:27.219\n改善患者的生活质量。\n\n15:28.672 --> 15:31.122\n体力活动循序渐进。\n\n15:31.122 --> 15:31.622\n指南。\n\n15:33.255 --> 15:42.554\n包括活动强度分级、适用人群阶段性活动计划制定、活动中监测与调整原则以及呼吸功能协同训练方法。\n\n15:44.359 --> 15:46.258\n七长期随访与自我管理。\n\n15:47.275 --> 15:51.474\n建议患者在出院后第一个月、第三个月和第6个月进行随访，\n\n15:51.525 --> 15:53.424\n之后每年至少随访一次，\n\n15:53.525 --> 15:55.474\n以便及时监测病情变化。\n\n15:55.575 --> 16:05.674\n主要监测指标包括胸部影像学检查、评估胸腔积液量及肺部情况、胸腔积液肿瘤指标监测以及血常规、肝肾功能等实验室检查。\n\n16:07.431 --> 16:11.330\n定期评估患者呼吸困难、胸痛、咳嗽等症状的严重程度，\n\n16:11.681 --> 16:16.330\n同时关注活动、耐力、营养状况及心理状态等生活质量指标。\n\n16:16.630 --> 16:19.481\n对随访中出发发现的异常情况，\n\n16:19.481 --> 16:21.205\n应及时通知患者就医，\n\n16:21.205 --> 16:22.830\n并协助调整治疗方案。\n\n16:23.421 --> 16:26.171\n将检查结果详细反馈给患者及家属，\n\n16:26.221 --> 16:27.921\n解释其临床意义，\n\n16:27.921 --> 16:28.995\n解答疑惑，\n\n16:28.995 --> 16:32.221\n确保患者了解自身病情、居家症状，\n\n16:32.221 --> 16:33.221\n自我评估方法。\n\n16:34.130 --> 16:34.531\n包括，\n\n16:34.681 --> 16:36.781\n主要包括呼吸困难评估，\n\n16:36.830 --> 16:38.580\n胸痛性质、频率评估，\n\n16:38.580 --> 16:43.830\n体温、体重动态追踪以及引流液性状与量的观察、警示，\n\n16:43.830 --> 16:45.931\n症状识别与就医指导。\n\n16:47.664 --> 16:48.914\n呼吸困难相关警示，\n\n16:48.914 --> 16:50.789\n出现静息状态下呼吸困难，\n\n16:50.789 --> 16:52.114\n端坐呼吸发干，\n\n16:52.213 --> 16:55.263\n或原有呼吸困难在短期内显著加重，\n\n16:55.364 --> 16:59.263\n提示胸腔积液量可能快速增加或肺功能严重受损，\n\n16:59.263 --> 17:00.364\n应立即就医。\n\n17:00.614 --> 17:02.539\n若胸痛有间歇性钝痛，\n\n17:02.539 --> 17:04.963\n钝痛转为持续性剧烈疼痛，\n\n17:05.014 --> 17:07.688\n或伴随肩背部、腹部放射痛，\n\n17:07.688 --> 17:11.514\n可能提示肿瘤侵犯胸膜、胸壁或出现其他并发症，\n\n17:11.514 --> 17:12.514\n应立即就诊。\n\n17:12.813 --> 17:16.889\n出现高热、寒颤、大量咯血或血性胸水。\n\n17:16.889 --> 17:17.713\n意识改变。\n\n17:17.920 --> 17:22.069\n极度乏力、短期内体重快速下降等全身症状恶化表现，\n\n17:22.219 --> 17:24.219\n需尽快就医评估病情。\n\n17:25.026 --> 17:28.501\n胸腔穿刺或引流后出现持续胸痛、呼吸困难，\n\n17:28.501 --> 17:34.802\n加重大量泡沫痰或引流液颜色异常、引流量骤增或骤减，\n\n17:34.802 --> 17:36.477\n应立即联系医护人员。\n\n17:37.753 --> 17:39.753\n八诊疗展望与研究进展。\n\n17:40.713 --> 17:42.213\n新型靶向药物的研发。\n\n17:44.109 --> 17:45.285\n抗血管生成药物，\n\n17:45.285 --> 17:52.310\n重组人血管内皮抑制素单药胸腔灌注治疗严重胸腔恶性胸腔积液，\n\n17:52.310 --> 17:54.609\n客观缓解率优于顺铂单药，\n\n17:54.760 --> 17:57.359\n尤其对血性胸腔积液效果显著，\n\n17:57.410 --> 17:59.685\n且与顺铂联用具有协同作用，\n\n17:59.685 --> 18:01.734\n能改善患者生活质量，\n\n18:01.734 --> 18:03.310\n不显著增加不良反应。\n\n18:03.560 --> 18:07.560\n另外靶向药物胸腔内应用探索包括贝伐珠单抗。\n\n18:09.316 --> 18:10.740\n它也可单药使用，\n\n18:10.740 --> 18:12.765\n可与顺铂联合使用，\n\n18:12.765 --> 18:16.166\n两到三周后根据积液情况可重复用药。\n\n18:16.215 --> 18:19.765\n在晚期非小细胞肺癌伴恶性胸腔积液中，\n\n18:19.765 --> 18:22.965\n显示出较高控制率和良好耐受性。\n\n18:23.166 --> 18:25.465\n另外一些新型硬化剂的研发，\n\n18:25.515 --> 18:27.015\n包括聚维酮碘。\n\n18:28.402 --> 18:29.453\n洛伯等。\n\n18:31.578 --> 18:32.628\n微创技术创新。\n\n18:34.557 --> 18:43.608\n包括内科胸腔镜技术的优化、经皮介入治疗器材的革新、智能引流系统的开发以及机器人辅助微创手术的探索。\n\n18:46.116 --> 18:47.416\n以上就是我的全部分享，\n\n18:47.416 --> 18:47.866\n谢谢。\n\n","v0d47cg10004d70bfviljht19fvvtnrg",1133,651,"2026-01-26 11:06:48","快速会议记录指南 - 高效会议技巧与工具分享  ","会议记录,高效会议,会议技巧,会议工具,快速记录,会议管理,职场效率  ","本视频为您提供快速会议记录的实用技巧与工具推荐，帮助您提升会议效率，掌握高效会议记录方法，优化职场工作流程。适合所有需要提高会议效率的职场人士观看学习。","2026-04-23 11:30:00",[36],{"menuId":37,"menuName":38,"parentId":21,"orderNum":39,"path":40,"component":41,"isFrame":42,"isCache":43,"menuType":44,"visible":25,"status":21,"createDept":6,"remark":17,"createTime":45,"children":46,"columnImage":47,"columnLogo":48,"uncheckedLogo":6,"checkedLogo":6,"isHot":21,"isHome":21,"forceLogin":21,"color":6,"seoTitle":49,"seoKeywords":50,"seoDescription":51,"contentNum":6,"promotionalPoster":52,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":53,"routerPath":40,"componentInfo":41},"1986622624134549505","科普视频",3,"video","/video.html","1","0","T","2025-11-07 10:31:58",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:09:40/0d7fcb56-3dc4-4dcb-99ca-a5d5c438378e.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:09:43/958efac7-dd02-4681-b8fd-0dd84b1bbf42.png","健康科普视频大全,了解你的健康生活","健康科普视频, 戒烟视频, 饮食健康视频, 胸痛科普, 用药知识, 职业健康视频, 贫血科普, 眼健康视频","精选健康科普视频,涵盖戒烟、胸痛、饮食、用药与职业健康等多个主题,让你轻松获取科学健康知识,提升生活质量。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:09:45/fa8fe113-deaa-4454-8105-d629769963dd.png","Video",2,"https://vod.haohuanjiao.com/huanjiao/specialistVideo/871759/6c7f0b2b-7f77-4b10-a7cd-28572d581778.tmp?a=0&auth_key=1789022119-d6808a7d99d340128cfcdfbadb1b77ad-0-d4752b5e63d1771e7628490a2c7f3867&br=381&bt=381&cd=0%7C0%7C0&ch=0&cr=0&cs=0&dr=0&ds=3&eid=v0d47cg10004d70bfviljht19fvvtnrg&er=0&l=202608110416274F352EA5EDAFD08195F1&lr=&mime_type=video_mp4&net=0&pl=0&qs=13&rc=anF5aTRrb3llOjczNGY3M0ApdXd5PHdtbGkzZzMzajpneWdvcXM2cWdmYy1hLS1kNGFzc2Rrc2MuZWlzXzQxLS5gMS06Yw%3D%3D&vl=&vr=",true,{"code":9,"msg":55,"message":6,"data":6,"success":56},{"code":9,"msg":10,"message":6,"data":59,"success":56},{"pageNo":25,"pageSize":60,"result":61,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":63,"success":56},{"authors":64,"appraiseDimensionScoresVos":65},[],[]]